“Javier’s extensive expertise leading interdisciplinary scientific teams at the U.S. Food and Drug Administration (FDA), combined with his deep experience within the uniformed services in the fields ...

Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

For decades, the United States held unrivalled global leadership in science and technology, based on its world-class research universities, high levels of public and private investment, and a policy ...

This year, the Department of Defense was authorized to spend $34 billion more on research and development than it was two years ago and only $18 billion more on procurement of new aircraft and ships.

The North Lawn of the White House in Washington, D.C., on Nov. 18, 2022. (Photo by MANDEL NGAN/AFP via Getty Images) The Office of Science and Technology Policy is looking for public input to revise a ...

EXCLUSIVE – The War Department is narrowing its research and development strategy to six "Critical Technology Areas" officials say will speed up innovation and strengthen America’s military edge.

While the 2025-2030 Dietary Guidelines for Americans (DGA) reinforces existing priorities rather than upend them, for ...

NEW YORK (November 18, 2025) — Beyond the Science: How People, Process, and Systems Transform the Business of Life Sciences by Gary K. Zammit, PhD, is now available on Amazon and at major booksellers.

At Praxis, Dr. Devinsky will be part of the group leading clinical strategy and global medical affairs, guiding program architecture, evidence generation, and external scientific engagement as the ...

The Trump Administration’s newly released Fiscal Year (FY) 2027 Research and Development Budget Priorities and Cross-Cutting Actions memorandum represents a fundamental realignment of federal science ...

TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics (PSTX), Inc. (NASDAQ: PSTX, President and CEO: ...

- Collaboration to Utilize CytomX’s Novel Probody ® Technology Platform for CD3 Bispecific Targets - - CytomX to Receive $80 Million Upfront Payment and Ability to Exercise Option for U.S.